“Orthosteric cannabinoid receptor 1 (CB1) activation leads to decreases in intraocular pressure (IOP).
The purpose of this study was to investigate the effects of the novel CB1-positive allosteric modulator (PAM) GAT229 on IOP.
The CB1 PAM GAT229 reduces IOP in ocular hypertensive mice and enhanced CB1-mediated IOP reduction when combined with subthreshold CB1 orthosteric ligands in normotensive mice. Administration of CB1 PAMs may provide a novel approach to reduce IOP with fewer of the disadvantages associated with orthosteric CB1 activation.”
https://www.ncbi.nlm.nih.gov/pubmed/28719234
